更新于：2024-12-19
Voriconazole
伏立康唑
更新于：2024-12-19
概要
基本信息
药物类型 小分子化药 |
别名 (R-(R*,S*))-alpha-(2,4-difluorophenyl)-5-fluoro-beta-methyl-alpha-(1H-1,2,4-triazol-1-ylmethyl)-4-pyrimidineethanol、(αR,βS)-α-(2,4-difluorophenyl)-5-fluoro-β-methyl-α(1H-1,2,4-triazol-1-ylmethyl)-4-pyrimidineethanol、Inhaled Voriconazole + [18] |
靶点 |
作用机制 CYP51A1抑制剂(细胞色素P450家族成员51抑制剂) |
原研机构 |
非在研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评优先审评 (中国) |
登录后查看时间轴
结构
分子式C16H14F3N5O |
InChIKeyBCEHBSKCWLPMDN-MGPLVRAMSA-N |
CAS号137234-62-9 |
关联
246
项与 伏立康唑 相关的临床试验注射用伏立康唑（0.2g）在中国健康成人中单次/多次给药的药代动力学和安全性试验以及单次给药的人体生物等效性试验
Comparing the Efficacy of Oral 200 Milligram Voriconazole Once a Day Vs. Twice a Day in the Treatment of Resisitant Dermatophyte Infections (Tinea Corporis and Tinea Cruris)
A Phase I, Two-part, Single-center, Open-label, Drug-drug Interaction Study to Assess the Effect of Voriconazole (Part 1) and Quinidine (Part 2) on the Pharmacokinetics of a Single Dose of Repotrectinib (BMS-986472) in Healthy Participants
100 项与 伏立康唑 相关的临床结果
登录后查看更多信息
100 项与 伏立康唑 相关的转化医学
登录后查看更多信息
100 项与 伏立康唑 相关的专利（医药）
登录后查看更多信息
7,738
项与 伏立康唑 相关的文献（医药）2025-12-01JOURNAL OF CLINICAL IMMUNOLOGY
Characteristics of Endemic Mycoses Talaromyces marneffei Infection Associated with Inborn Errors of Immunity
Review
作者: Xing, Shubin ; Zhao, Xiaodong ; Tang, Xuemei ; Zhang, Zhenzhen ; An, Yunfei ; Liu, Cong ; He, Wuyang ; Chen, Yongwen ; Zhang, Wenjing ; Zhang, Zhiyong
BACKGROUND:
Talaromyces marneffei (T. marneffei) is an opportunistic pathogen that causes endemic mycoses, which could lead to multiple organ damage. Talaromycosis is frequently disregarded as an early cautionary sign of immune system disorders in non-HIV-infected children.
OBJECTIVE:
We conduct a comprehensive review of the genotypes and clinical features of talaromycosis in patients with IEI to enhance clinical awareness regarding T. marneffei as a potential opportunistic pathogen in individuals with immune deficiencies.
METHODS:
A systematic literature review was performed by searching PubMed, Cochrane Central Register of Controlled Trials, Web of Science, EMBASE, and Scopus. Data on IEI patients with talaromycosis, including genotypes and their immunological and clinical features, were collected.
RESULTS:
Fifty patients with talaromycosis and IEI were included: XHIM (30.0%), STAT3-LOF deficiency (20.0%), STAT1-GOF (20.0%), IL2RG (6.00%), IFNGR1 (6.0%), IL12RB1 (4.0%), CARD9 (4.0%), COPA (4.0%), ADA (2.0%), RELB deficiency (2.0%), and NFKB2 (2.0%). Common symptoms of respiratory (43/50, 86.0%), skin (17/50, 34.0%), lymph node (31/50, 62.0%), digestive (34/50, 68.0%), and hematologic (22/50, 44.0%) systems were involved. The CT findings of the lungs may include lymph node calcification (9/30), interstitial lesions (8/30), pulmonary cavities (8/30), or specific pathogens (4/30), which could be easily misdiagnosed as tuberculosis infection. Amphotericin B (26/43), Voriconazole (24/43) and Itraconazole (22/43) were used for induction therapy. Ten patients were treated with Itraconazole sequentially and prophylaxis. 68.0% (34/50) of patients were still alive, and 4.0% (2/50) of were lost to follow-up. The disseminated T. marneffei infection resulted in the deaths of 14 individuals.
CONCLUSIONS:
The XHIM, STAT1-GOF, and STAT3-LOF demonstrated the highest susceptibility to talaromycosis, indicating the potential involvement of cellular immunity, IL-17 signaling, and the IL-12/IFN-γ axis in T. marneffei defense. T. marneffei infection may serve as an early warning indicator of IEI. For IEI patients suspected of T. marneffei, metagenomic next-generation sequencing (mNGS) could rapidly and effectively identify the causative pathogen. Prompt initiation of antifungal therapy is crucial for optimizing patient outcomes.
2025-12-01JOURNAL OF CLINICAL IMMUNOLOGY
Disseminated Aspergillosis in X-linked Agammaglobulinemia: Beyond the norm
Article
作者: Rawat, Amit ; Vignesh, Pandiarajan ; Jindal, Ankur Kumar ; Thangaraj, Abarna ; Goel, Sumit ; Sil, Archan
X-linked agammaglobulinemia (XLA) due to a mutation in Bruton's tyrosine kinase (BTK), leads to the arrested development of B cells at the pro-B cell stage. This results in absent B cells and severe hypogammaglobulinemia. XLA patients usually present with recurrent sinopulmonary infection. Bacterial infections are the commonest [2], fungal infections like Pneumocystis jirovecii, Aspergillus and Candida species are rarely reported and they are associated with mortality in XLA [3]. We report a 3.5-year-old boy with disseminated aspergillosis, an uncommon presentation of XLA. Despite treatment with antifungals, including voriconazole and amphotericin B, the patient succumbed to the illness. Genetic analysis revealed a pathogenic variant in the BTK gene (R28H), confirming XLA diagnosis. This case highlights the potential for severe fungal infections in XLA patients and suggests broader immune system dysregulation beyond B-cell defects.
2025-12-01CANCER CHEMOTHERAPY AND PHARMACOLOGY
Pharmacokinetic analysis of crushed venetoclax tablets combined with azacitizine for recurrent pediatric acute myeloid leukemia (AML)
Article
作者: Yasu, Takeo ; Yuza, Yuki ; Makimoto, Atsushi ; Matsui, Motohiro
BACKGROUND:
The efficacy of a combination therapy consisting of venetoclax (VEN) and azacytidine (AZA) for newly diagnosed acute myeloid leukemia (AML) has been confirmed in elderly patients. However, the clinical data on VEN for pediatric AML are limited. A combination therapy consisting of crushed VEN tablets and AZA (VEN/AZA) was administered to two children with recurrent AML. The pharmacokinetics of VEN were then analysed.
CASE PRESENTATION:
[Patient 1] A 1-year-old, male patient who experienced an AML relapse following an allogeneic hematopoietic stem cell transplantation received three courses of VEN/AZA. At the initial dosage of VEN (8 mg/kg), the minimum plasma concentration (Cmin) was only 0.44 µg/ml, which was far less than the optimal Cmin of 1.2 µg/ml. Subsequent dose-escalation to 10 mg/kg only achieved Cmin 0.42 µg/ml. [Patient 2] A 3-year-old, female patient in whom infantile acute lymphoblastic leukemia was originally diagnosed experienced a recurrence in the form of AML after lineage-switching. Three courses of VEN/AZA were administered with the same therapeutic drug monitoring as in Case 1. The Cmin of VEN was 0.15 µg/ml at 8 mg/kg. Afterwards, voriconazole 16 mg/kg/day was begun for a concomitant fungal infection together with VEN 2 mg/kg. This combination finally achieved Cmin 1.14 µg/ml probably through CYP3A4 inhibition by voriconazole. In terms of safety, only grade 4 hematological adverse events were observed in both patients. In terms of efficacy, patient 1 and patient 2 achieved stable disease status for two months and six months, respectively.
CONCLUSION:
Pediatric patients may scarcely achieve effective plasma concentration of VEN when crushed tablets are used at the same dosage as in adults.
100 项与 伏立康唑 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 侵袭性念珠菌病 | 欧盟 | 2013-05-16 | |
| 侵袭性念珠菌病 | 冰岛 | 2013-05-16 | |
| 侵袭性念珠菌病 | 列支敦士登 | 2013-05-16 | |
| 侵袭性念珠菌病 | 挪威 | 2013-05-16 | |
| 茎孢子虫病 | 美国 | 2003-12-19 | |
| 系统性念珠菌病 | 澳大利亚 | 2002-09-03 | |
| 镰刀菌病 | 美国 | 2002-05-24 | |
| 念珠菌血症 | 欧盟 | 2002-03-19 | |
| 念珠菌血症 | 冰岛 | 2002-03-19 | |
| 念珠菌血症 | 列支敦士登 | 2002-03-19 | |
| 念珠菌血症 | 挪威 | 2002-03-19 | |
| 念珠菌病 | 欧盟 | 2002-03-19 | |
| 念珠菌病 | 冰岛 | 2002-03-19 | |
| 念珠菌病 | 列支敦士登 | 2002-03-19 | |
| 念珠菌病 | 挪威 | 2002-03-19 | |
| 侵袭性曲霉菌病 | 欧盟 | 2002-03-19 | |
| 侵袭性曲霉菌病 | 冰岛 | 2002-03-19 | |
| 侵袭性曲霉菌病 | 列支敦士登 | 2002-03-19 | |
| 侵袭性曲霉菌病 | 挪威 | 2002-03-19 | |
| 侵袭性真菌感染 | 欧盟 | 2002-03-19 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 白血病 | 临床3期 | 美国 | 2009-05-01 | |
| 肺曲霉菌病 | 临床3期 | 法国 | 2005-07-01 | |
| 发热 | 临床3期 | 德国 | 2005-01-01 | |
| 腔内曲霉菌球 | 临床2期 | 日本 | 2011-09-01 | |
| 全身性真菌病 | 临床2期 | 美国 | 2008-06-01 | |
| 中性粒细胞减少 | 临床2期 | - | 2003-06-01 | |
| 侵袭性肺曲霉菌病 | 临床2期 | - | - | |
| 真菌性角膜炎 | 临床1期 | 中国 | 2023-07-17 | |
| 哮喘 | 临床1期 | 澳大利亚 | 2020-11-15 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 20 | 壓願鹽繭網餘築積膚遞(獵積齋築壓繭積夢鏇憲) = 範顧製觸廠糧網餘顧獵 醖夢繭積醖鬱築淵鹹顧 (範範觸鏇遞顧獵範簾壓 ) 更多 | 不佳 | 2024-05-14 | |||
GlobeNewswire 人工标引  | 临床2期 | 9 | TFF VORI | 網鹽選製窪夢築遞蓋襯(鬱鹹夢願艱夢壓繭遞淵) = 鑰窪製鬱餘獵積簾齋衊 壓顧餘襯鑰網齋廠廠製 (製願構窪鑰構願淵願鏇 ) 更多 | 积极 | 2023-12-19 | |
- | |||||||
临床1期 | - | 48 | 廠襯範餘積衊膚鬱夢鹹(顧憲構鹽壓遞膚窪衊鹹) = 製憲窪製鹽蓋願廠鏇鹽 齋簾遞壓廠淵繭膚艱壓 (積築窪築衊壓蓋廠夢築 ) 更多 | - | 2023-03-03 | ||
廠襯範餘積衊膚鬱夢鹹(顧憲構鹽壓遞膚窪衊鹹) = 鹽淵淵積鬱鬱窪構製願 齋簾遞壓廠淵繭膚艱壓 (積築窪築衊壓蓋廠夢築 ) 更多 | |||||||
临床3期 | 189 | (TDM group) | 製廠簾願積鬱選積積遞(壓遞膚餘齋鹹鏇餘築築) = 積製築網簾遞餘製鏇願 壓憲膚齋製衊膚構淵膚 (鏇憲繭憲齋鏇鏇窪鬱願 ) | - | 2023-01-12 | ||
(non-TDM group) | 製廠簾願積鬱選積積遞(壓遞膚餘齋鹹鏇餘築築) = 鬱襯壓範遞獵鹹築壓願 壓憲膚齋製衊膚構淵膚 (鏇憲繭憲齋鏇鏇窪鬱願 ) | ||||||
N/A | - | 468 | Voriconazole (VCZ) | 醖襯顧艱顧築壓壓製糧(齋選鏇願觸廠衊鹽壓鬱) = 鹹醖糧齋鹽遞膚鹽製積 網襯網蓋齋範壓壓築簾 (蓋製膚顧鹽餘夢壓蓋顧 ) 更多 | 积极 | 2022-03-01 | |
N/A | - | 夢遞廠齋夢鬱選築鏇鬱(衊淵蓋鹽築餘廠範簾遞): aOR = 0.543 (95% CI, 0.338 ~ 0.872) 更多 | - | 2022-01-01 | |||
N/A | 67 | 築鑰醖窪蓋衊築遞範糧(鹽夢製襯淵壓廠艱糧壓) = 窪淵膚鹹選簾顧壓積鏇 鏇蓋願遞願憲餘鹹積鹹 (積淵醖襯壓選鬱淵鹹廠 ) 更多 | 积极 | 2021-09-01 | |||
築鑰醖窪蓋衊築遞範糧(鹽夢製襯淵壓廠艱糧壓) = 範艱齋鏇鏇鏇醖願憲積 鏇蓋願遞願憲餘鹹積鹹 (積淵醖襯壓選鬱淵鹹廠 ) 更多 | |||||||
N/A | 造血干细胞移植 CYP2C19*17 | 70 | Letermovir prophylaxis | 淵遞製獵醖夢襯襯鏇鑰(壓糧醖簾壓簾製願襯衊) = 範積餘積鑰願鑰醖淵鏇 醖餘獵獵壓蓋範膚蓋鹹 (顧顧壓糧鹽窪廠鏇醖蓋 ) | - | 2021-03-01 | |
No Letermovir prophylaxis | 淵遞製獵醖夢襯襯鏇鑰(壓糧醖簾壓簾製願襯衊) = 窪壓觸鹽鬱壓觸繭壓築 醖餘獵獵壓蓋範膚蓋鹹 (顧顧壓糧鹽窪廠鏇醖蓋 ) | ||||||
N/A | - | - | 襯繭壓構憲廠鏇餘艱鹽(遞繭鏇鏇廠鏇繭積範簾) = 觸餘選餘製範壓糧構構 積網艱醖鑰夢積膚願構 (襯構窪築衊鬱廠鬱簾膚 ) | - | 2020-06-01 | ||
襯繭壓構憲廠鏇餘艱鹽(遞繭鏇鏇廠鏇繭積範簾) = 糧醖膚網醖餘選齋艱壓 積網艱醖鑰夢積膚願構 (襯構窪築衊鬱廠鬱簾膚 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用